Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alterity Therapeutics Ltd ADR
(NQ:
ATHE
)
1.285
+0.005 (+0.39%)
Streaming Delayed Price
Updated: 3:46 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
23,946
Open
1.300
Bid (Size)
1.220 (1)
Ask (Size)
1.400 (10)
Prev. Close
1.280
Today's Range
1.230 - 1.319
52wk Range
1.010 - 5.410
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
October 11, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
October 02, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Performance
YTD
-48.19%
-48.19%
1 Month
+1.98%
+1.98%
3 Month
-39.81%
-39.81%
6 Month
-47.55%
-47.55%
1 Year
-47.12%
-47.12%
More News
Read More
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
September 30, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
September 23, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
July 31, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Present at MST Financial Webinar
July 24, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
July 17, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
June 12, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
May 29, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
May 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 10, 2024
Via
Benzinga
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
May 08, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 03, 2024
Via
Benzinga
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
April 30, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
April 29, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 23, 2024
Via
Benzinga
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 17, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
April 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
April 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 15, 2024
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Via
Benzinga
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
April 10, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
March 26, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
February 20, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.